Blog
RSS FeedPosted by Michael Wonder on 28 Jan 2020
Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime
27 January 2020 - Jubilant Radiopharma announced today that the company received approval from Health Canada for Drax Exametazine (Kit ...
Posted by Michael Wonder on 28 Jan 2020
Health Canada approves new indication for Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis
27 January 2020 - In the Phase 3 pivotal trial, nearly 44% of patients receiving Stelara subcutaneous injections every 8 ...
Posted by Michael Wonder on 24 Jan 2020
Ready for rescue – new nasally administered glucagon for severe hypoglycaemia available in Canada
23 January 2020 - Eli Lilly Canada introduces Baqsimi, another Canadian innovation to help manage diabetes complications. ...
Posted by Michael Wonder on 24 Jan 2020
HLS Therapeutics files new drug submission for Perseris in Canada
23 January 2020 - If approved by Health Canada, Perseris would become the first once-monthly risperidone long-acting injectable used in the ...
Posted by Michael Wonder on 24 Jan 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with advanced renal cell carcinoma
23 January 2020 - Approval based on results of KEYNOTE-426, Where Keytruda in combination with axitinib reduced the risk of death ...
Posted by Michael Wonder on 16 Jan 2020
Cimzia (certolizumab pegol) now approved in Canada for the treatment of non-radiographic axial spondyloarthritis
15 January 2020 - UCB Canada announced today that Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults ...
Posted by Michael Wonder on 15 Jan 2020
Health Canada approves Astellas' Xospata (gilteritinib) for patients with relapsed or refractory acute myeloid leukaemia with a FLT3 mutation
14 January 2020 - Xospata is the first and only targeted treatment approved by Health Canada for patients with relapsed or ...
Posted by Michael Wonder on 09 Jan 2020
New treatment approved in Canada for most common type of leukaemia
8 January 2020 - Calquence (acalabrutinib) is now available for adult patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. ...
Posted by Michael Wonder on 08 Jan 2020
AbbVie receives Health Canada approval of Rinvoq (upadacitinib), an oral medication for the treatment of adults with moderate to severe active rheumatoid arthritis
7 January 2020 - Approval supported by efficacy and safety data from the pivotal Phase 3 SELECT rheumatoid arthritis program, one ...
Posted by Michael Wonder on 02 Jan 2020
HLS Therapeutics announces Health Canada approval for Vascepa to reduce the risk of cardiovascular events
1 January 2020 - Health Canada approval follows priority review for Vascepa. ...
Posted by Michael Wonder on 17 Dec 2019
Health Canada approves new indication for Erleada (apalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 December 2019 - Janssen announced today that Health Canada, following a priority review, has approved Erleada (apalutamide) for the ...
Posted by Michael Wonder on 13 Dec 2019
Novartis completes certification of initial sites in Ontario for first approved Canadian CAR-T therapy, Kymriah (tisagenlecleucel)
12 December 2019 - Ontario government to reimburse Kymriah therapy for certain patients with life-threatening cancers who are in critical need. ...
Posted by Michael Wonder on 12 Dec 2019
Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 December 2019 - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine has ...
Posted by Michael Wonder on 07 Dec 2019
International collaboration among Canadian, U.S. and Australian regulators leads to new options for the treatment of cancer
6 December 2019 - Health Canada also provides an update on approvals of new drugs and medical devices for Canadians. ...
Posted by Michael Wonder on 04 Dec 2019
Health Canada grants priority review status for Heron Therapeutics' new drug submission for HTX-011 for management of post-operative pain
3 December 2019 - Heron Therapeutics today announced that Heron's new drug submission for HTX-011 for the management of postoperative pain ...